Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
2019
Objective
To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
28
References
13
Citations
NaN
KQI